MedPath

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

Completed
Conditions
Leukemia
Neurotoxicity
Psychosocial Effects of Cancer and Its Treatment
Long-term Effects Secondary to Cancer Therapy in Children
Registration Number
NCT00085176
Lead Sponsor
Children's Oncology Group
Brief Summary

RATIONALE: Cancer therapies may affect the ability of a child's brain and central nervous system to function normally. Learning to identify which patients will develop complications may improve the ability of doctors to plan cancer treatment and improve patient quality of life.

PURPOSE: This clinical trial is studying neurobehavioral changes in children who have received steroid therapy or intrathecal therapy for acute lymphoblastic leukemia.

Detailed Description

OBJECTIVES:

* Compare neurobehavioral functioning, specifically memory, attention, executive function, visual-motor integration, and processing speed, in children previously treated with steroids (prednisone vs dexamethasone) and intrathecal therapy (methotrexate alone vs methotrexate, cytarabine, and hydrocortisone) for childhood acute lymphoblastic leukemia.

* Correlate non-treatment risk factors, such as gender, age at diagnosis, and time since termination of prior therapy, with impaired neurobehavioral function in these patients.

* Correlate neurobehavioral complications with quality-of-life of these patients.

OUTLINE: This is a multicenter, cohort study. Patients are assigned to 1 of 2 cohorts (prior treatment per CCG-1922 \[prednisone vs dexamethasone\] vs prior treatment per CCG-1952 \[intrathecal (IT) methotrexate vs IT methotrexate, cytarabine, and hydrocortisone\]). Patients in each cohort are stratified according to age at diagnosis, gender, and time since prior treatment termination.

* Cohort A (CCG-1922): Patients undergo physical and neurological examination, neurobehavioral evaluation, and quality of life assessment. Neurobehavioral evaluations assess memory, attention, and executive function.

* Cohort B (CCG-1952): Patients undergo evaluation as above. Neurobehavioral evaluations assess visual-motor integration and processing speed.

PROJECTED ACCRUAL: A total of 448 patients (224 per cohort) will be accrued for this study within 4 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
286
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Two-sided comparisons of various mean neurobehavioral scores between the two treatment arms within each studylength of study

Data analysis for each of the two clinical trials will be conducted separately. The primary objectives will be two-sided comparisons of various mean neurobehavioral scores between the two treatment arms within each study.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

Children's Hospital Center for Cancer and Blood Disorders

๐Ÿ‡บ๐Ÿ‡ธ

Aurora, Colorado, United States

Indiana University Melvin and Bren Simon Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

Children's Hospitals and Clinics of Minnesota - Minneapolis

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Vanderbilt-Ingram Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

Phoenix Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

NYU Cancer Institute at New York University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Jonathan Jaques Children's Cancer Center at Miller Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Long Beach, California, United States

Children's Hospital and Research Center Oakland

๐Ÿ‡บ๐Ÿ‡ธ

Oakland, California, United States

Children's Hospital and Regional Medical Center - Seattle

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center

๐Ÿ‡บ๐Ÿ‡ธ

Farmington, Connecticut, United States

Cincinnati Children's Hospital Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Cincinnati, Ohio, United States

Loma Linda University Cancer Institute at Loma Linda University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Loma Linda, California, United States

C.S. Mott Children's Hospital at University of Michigan Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Ann Arbor, Michigan, United States

Jonsson Comprehensive Cancer Center at UCLA

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Alfred I. duPont Hospital for Children

๐Ÿ‡บ๐Ÿ‡ธ

Wilmington, Delaware, United States

Childrens Hospital Los Angeles

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Yale Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

Butterworth Hospital at Spectrum Health

๐Ÿ‡บ๐Ÿ‡ธ

Grand Rapids, Michigan, United States

Oregon Health and Science University Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Masonic Cancer Center at University of Minnesota

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Nationwide Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

Children's Hospital of Pittsburgh

๐Ÿ‡บ๐Ÿ‡ธ

Pittsburgh, Pennsylvania, United States

Primary Children's Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Salt Lake City, Utah, United States

Lucille P. Markey Cancer Center at University of Kentucky

๐Ÿ‡บ๐Ÿ‡ธ

Lexington, Kentucky, United States

Children's National Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Blank Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Des Moines, Iowa, United States

Holden Comprehensive Cancer Center at University of Iowa

๐Ÿ‡บ๐Ÿ‡ธ

Iowa City, Iowa, United States

Children's Mercy Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Missouri, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

๐Ÿ‡บ๐Ÿ‡ธ

Chapel Hill, North Carolina, United States

Children's Hospital of Philadelphia

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

M. D. Anderson Cancer Center at University of Texas

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath